We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Https://uk.finance.yahoo.com/screener/insider/First%20Lucre%20Partnership%20Company
Interesting article and true. The next results will show profit because of the 15.9m and no doubt the next milestone payment from sanofi. So could be around £20m in revenue….add the cash and assets currently hold and an mcap of now less than 20m is kinda silly. Only retail shorts on this trying to get it down. Will keep adding as this will jump up quick shortly.
Agree with that. Looks like double bottom in. Squeeze time.
Well fwiw I am calling the bottom on these now.
Bring on the buyers and milestone payments which will be significant in Q1 2024.
I can wait and have the patience to outlast the short term girations here.
Good Luck to all genuine investors here for 2024.
Why would anyone short this now where current MCap is represented mostly by cash and there are partnered and other cash generating opportunities in the pipeline. Maybe someone auditioning for Brewsters Milluons 2
Amazing how that one short opened this morning has pushed it down but so difficult to buy.
FYI. All shorts now closed on C4xd this afternoon on IG. Had been a couple of short positions. They’ve closed out. Could be close to getting a blue finish to set it up nicely for the next few weeks/months. Remember the 50% plus open on the az news.
Yep something around that figure which is tiny. Avacta for example free float is around 90%. Even the likes of asos and boo is 50%
Quite a few of the holders are very close to tr1 threshold. Polar for example close to go 18%
Free Float is @20%....???
As it is under the radar. The wide spread doesn’t help as putting off buyers/traders. Lombard keep buying and one of those chunkier trades could have been a director buy today. Once it picks up it should move quite quickly as free float is small
Then again Shore Cap do make some very good calls IMO FWIW so why is no one buying at this massive discount?
Shore says Fair Value 55p.......wtf????
Could be well timed. I got the same. Had hovered at 8.15 but then it jumped. 8.66 to buy now. Some chunky trades today
Just added at 8.3p (shown on LSE as a sale) so reduced my average from 21p to 12p to keep within range should C4X become a takeover target. I’m positive on this company and see this as a bargain share. IMO and DYOR. Directors buying (if they can) would be nice and why wouldn’t they at this price?
Just as I posted. Broker note out and agree with it.
Yet investors may be tardy to the party, according to analysts: "We feel the recent weakness in the shares look unwarranted and would seem to discount some if not all of the potential we see across the pipeline."
https://www.proactiveinvestors.co.uk/companies/news/1036203/c4x-discovery-deals-a-strong-validation-of-prowess-in-drug-discovery-analyst-1036203.html?viewSource=TwitterUK
Bought. Watched the presentation. They deliver and as they say are in a rhythm now. To cheap and see a few bits of potential news in coming weeks/months that will validate this.
Looking back in here. Noticed it falling last few weeks. Very cheap when considering cash now and net assets vs mcap. They sign posted sanofi milestone payment which will be a few million too. They have a history of delivering. Director buys wouldn’t go a miss
Unfortunately I didn’t get on the analysts call but I see the 2023 full year results presentation has now been posted on the website - looks promising . It seems future milestone payments (next one Sandi) should keep the company cash flow positive for some time, we need to see how Immuno-Inflammation programmes bear fruit and enhance shareholder value as per revised strategy communicated to us back in July / August. The company normally gives a short interview with Proactive Investors so that should be worth looking out for.
The backward looking results were as expected, no shocks.
Nothing to warrant such a SP drop. Well funded and plenty of pipeline opportunities near inflection point.
Wakey - be interested to hear feedback from the analyst call, if you could?
Pretty much valued at Cash In The Bank now....no value associated to the actual business at all.
How bizarre is that?
No wonder so many companies are leaving the UK markets, what's the point being listed if markets can't even value a company beyond it's cash position?
Company should find a partner and sell itself to them asap and stick two fingers up to the UK markets.
This IMO is materially undervalued and I wonder if there has been a larger shareholder exiting that has caused the recent significant drop in the SP - no RNS to confirm though, mmmm. Also, I see there is an analyst call today at 9.30am but nothing for us PIs. I’m hoping to join the 9.30 call and see what they have to say. The results to 31 July 2023 are not particularly inspiring but the post period end and future outlook is far better
Indeed they are making good progress. Plenty to look forward to. Cash is enough for another 1,5 year.
In July we had about £21 million cash and assets of £6.5 million, let's allow research spending of £5million to present date....that leaves us with our present dp.....no premium for deals done or research to date ????
Green for the change!
I agree Wakey. I am going to hold tight and be patient.
I think the management team is good (albeit a bit lacking in comms) and the pipeline solid. Nothing has happened in the last six months to make me change my view. Until such time as the facts change, I will hold. And accumulate if it falls further.
Don't get it. MCap at this SP is around £20m yet they had cash received in August from Individor of £15.95m and the pre-existing cash runway should have taken us well into 2024. So you could say that the MCap is represented mainly by the cash balance. There is little debt in the group. Furhter milestone payments to come from Sanofi and Astra Zenenca unless they sell future rights for a lump sum (so further cash potential) like they did with Individor. Even if the results are awful how bad can it be to justify this low SP unless the company has been on a mad spending spree and spent a huge amount of the cash? Assuming that is not the case, what else could justufy the mad SP drop over the last 5 days?